Bayern Kapital, CD-Venture in series-C for TriOptoTec

The company will use the fresh capital to scale up its production facilities in response to this increased demand, according to a statement.

Bayern Kapital has 11 funds under management and focuses on companies based in Bavaria, generally investing €250,000-€600,000, although it can invest up to €2m in co-investments.

Previous funding
In June 2017, Bayern Kapital backed the first financing round for TriOptoTec.

Bayern Kapital and CD-Venture backed the €2m series-B round for TriOptoTec in February 2020, which also included participation from a number of angel investors.

Company
TriOptoTec has developed a product called Dyphox that uses a process based on photodynamics to disinfect surfaces, which it claims reduces decontamination by up to 99.9999%. The product is generally used as a spray solution for cleaning in hospitals, but also has applications in paints and varnishes. It is effective against viruses, bacteria, mould and spores, but is not harmful to humans, according to a statement.

The company was founded in 2017 as a spinout from the University of Regensburg Hospital. It is based in Regensburg and has 10 employees.

People
TriOptoTec – Xaver Auer (managing director).
Bayern Kapital – Georg Ried (managing partner).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Expansion
• DACH
• Healthcare
• Venture
• Germany
• coronavirus